Madopar

Levodopa / Benserazide, the active ingredient in Madopar, is a dopamine precursor with dopa decarboxylase inhibitor presented as an oral tablet for oral use. It treats Parkinson's disease and related Parkinsonian syndromes in adults. GNH USA supplies Madopar as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Madopar (Levodopa/Benserazide) is used in the management of Parkinsonian disorders by restoring central dopamine levels.

- Parkinson's disease: reduces motor symptoms such as bradykinesia, rigidity and tremor. - Parkinsonian syndrome: improves overall motor function and daily activity performance. - Levodopa‑responsive Parkinsonism: provides symptomatic relief by increasing central dopamine.

Common Side Effects: - Nausea - Vomiting - Dizziness or light‑headedness - Orthostatic hypotension - Headache - Insomnia

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or severe confusion - Severe orthostatic hypotension leading to falls - Cardiac arrhythmias - Neuroleptic malignant‑like syndrome - Anaphylactic or severe allergic reactions

When prescribing Madopar, clinicians should consider several safety measures. - Dose titration: start low and increase gradually to balance efficacy and tolerability. - Monitor for dyskinesia: adjust dose if involuntary movements appear. - Cardiovascular assessment: watch for orthostatic hypotension and arrhythmias. - Caution in narrow‑angle glaucoma: avoid exacerbation of intra‑ocular pressure. - Use carefully in hepatic or renal impairment: dose may require adjustment. - Store at ambient temperature: keep in the original pack, protect from moisture.

Madopar may interact with several medicines that affect dopamine pathways or metabolism.

Major Interactions (Avoid): - Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis. - Antipsychotics with strong D2 antagonism (e.g., haloperidol): may block therapeutic effect. - High‑dose pyridoxine (vitamin B6): accelerates peripheral levodopa metabolism. - MAO‑B inhibitors (e.g., selegiline) in high doses: potential for severe hypertension.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may enhance orthostatic hypotension. - SSRIs or SNRIs: monitor for serotonin syndrome. - Iron or calcium supplements: can reduce levodopa absorption; separate dosing by at least 2 hours. - Anticholinergics: may mask early signs of dopaminergic side effects. - Carbonic anhydrase inhibitors (e.g., acetazolamide): may increase plasma levodopa levels.